Intranasal Insulin Shows Potential for Treating PTSD Symptoms
A clinical trial is underway to assess the efficacy of intranasal insulin in reducing symptoms of PTSD.
Phase III
Neurology / PTSD
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial of intranasal insulin for PTSD could introduce a novel treatment option, potentially reshaping the therapeutic landscape for PTSD. Success in this trial may compel portfolio teams to reassess their strategies regarding PTSD therapies and consider integration of this new approach.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding efficacy and safety data.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.